Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • NCLAT stays eviction...

    NCLAT stays eviction of over Rs 9000 crore debt-ridden Sterling Biotech from its premises

    Farhat NasimWritten by Farhat Nasim Published On 2019-08-05T09:10:51+05:30  |  Updated On 5 Aug 2019 9:10 AM IST
    NCLAT stays eviction of over Rs 9000 crore debt-ridden Sterling Biotech from its premises

    The appellate tribunal observed that although Sterling Biotech, which is presently going through liquidation, is not the owner of the premises it cannot be ejected or disturbed during the moratorium period as the company has to remain as a going concern.


    New Delhi: The National Company Law Appellate Tribunal (NCLAT) has stayed eviction of Sterling Biotech from its premises as the debt-ridden company was going under the insolvency resolution process and was under the moratorium period.


    A two-member bench headed by NCLAT Chairman Justice S J Mukhopadhaya upheld the order passed by the Mumbai Bench of the National Company Law Tribunal (NCLT), which had asked Srei Infrastructure Finance, a financial creditor, to hand over the possession of the A and B wing premises of Laxmi Towers.


    The appellate tribunal observed that although Sterling Biotech, which is presently going through liquidation, is not the owner of the premises it cannot be ejected or disturbed during the moratorium period as the company has to remain as a going concern.


    "We hold that the Adjudicating Authority (NCLT) has rightly directed the Appellant to hand over the possession of ‘B’ Wing premises of Lakshmi Towers and rightly prohibited the Appellant from evicting the ‘Corporate Debtor (Sterling Biotech) from ‘A’ Wing premises of Lakshmi Towers," said NCLAT.


    However, it also said that "So far as the question as to who is the owner of ‘A’ and ‘B’ Wings premises of Lakshmi Towers and whether the Appellant has any right over the said property, such questions are not required to be determined in the proceeding under the ‘I&B Code’." NCLAT also said if Sterling Biotech is saved during the liquidation proceeding or if it is sold to a third party along with the employees then, in such case, one may move before the Competent Court of law for appropriate decision.


    Also Read: Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore


    Besides, the appellate tribunal also said that "the Liquidator cannot sell the assets of the premises in question."Resolution Professional of Sterling Biotech had moved NCLT against the financial creditor to return the possession of B Wing premises of Lakshmi Towers and restrain Srei Infrastructure Finance from taking any action in relation to A Wing premises, which had allowed it.


    Following which, Srei Infrastructure Finance moved NCLAT.


    It had contended that the property in question does not belong to Sterling Biotech and being a third party property, the order of ‘Moratorium’ passed under Section 14 of the ‘I&B Code’ will not be applicable.


    Opposing it, the RP had submitted that it amounts to obstruction in the matter of keeping Sterling Biotech as a going concern.


    Sterling Biotech, whose promoters Nitin Jayantilal Sandesara and Chetankumar Jayantilal Sandesara are absconding, has a total debt of over Rs 9,000 crore.

    Chetankumar Jayantilal Sandesaracorporate debtorInb CodeLakshmi TowersMumbaimumbai bench NCLTNational Company Law Appellate TribunalNCLATNCLTNitin Jayantilal Sandesarapharmapharma newspharma news indiaS J MukhopadhayaSection 14 inb codeSrei Infrastructure FinanceSterling Biotechsterling biotech insolvencySterling Biotech promoterssterling debt
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok